ArticleBMC chemistry2025
Development of molecularly imprinted polymers for the removal of levofloxacin.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecularly Imprinted Polymers Based on Cyclodextrin Derivatives and Chitosan for Selective Extraction of Drugs and Dyes.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extensive use of antibiotics and their persistence in the environment make them emerging pollutants of global concern, posing serious risks to ecosystems and public health. Among them, the broad-spectrum fluoroquinolone antibiotic levofloxacin (LEV) is widely prescribed for bacterial infections and has frequently been detected in freshwater systems and environmental matrices. Its presence is linked to the development of antibiotic resistance and ecological toxicity, underscoring the urgent need for efficient removal strategies. In this study, levofloxacin-imprinted polymers (LEV-MIPs) were developed using a precipitation polymerisation method. A set of nine LEV-MIPs was synthesised using three solvent combinations: ethanol: acetonitrile, ethanol: dimethyl sulfoxide, and ethanol: carbon tetrachloride. Methacrylic acid (MAA) served as the functional monomer (1-3 mmol), ethylene glycol dimethacrylate (EGDMA) as the cross-linker (16 mmol), and azobisisobutyronitrile (AIBN) as the initiator (0.1 mmol). Among them, two formulations (LEV3-MIP and LEV6-MIP) demonstrated superior removal efficiency. Structural and thermal characterisation by FTIR, SEM/EDX, and TGA confirmed successful polymer synthesis, with surface analysis revealing spherical, monodispersed particles of ~ 1.5 μm. Batch adsorption assays showed removal efficiencies of 97.85% (LEV3-MIP) and 99.15% (LEV6-MIP) under optimised conditions (15 ppm initial concentration, 0.3 mg dosage, pH 7, and 90 min and 60 min contact time, respectively). Both polymers exhibited high imprinting factors (3.081 and 3.359) and excellent reusability, with minimal efficiency loss of only 2.7% and 2.09% after ten adsorption-desorption cycles. These results highlight the strong potential of LEV-MIPs as cost-effective, selective, and reusable materials for mitigating antibiotic pollution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.